PLRX Pliant Therapeutics Inc
1,180
$12.13
$0.04
(0.33%)
| Watchers | 1,180 |
| 52-Wk Low | $11.21 |
| 52-Wk High | $24.74 |
| Market Cap | $731.75M |
| Volume | 447,621.00 |
| 52-Wk High | $24.74 |
| 52-Wk Low | $11.21 |
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In PatientsBenzinga • 18 days ago
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis...
Share to Feed
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
This indicator may be signaling that PLRX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
For the last three days, A.I.dvisor has detected that PLRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat.com...
For the last three days, A.I.dvisor has detected that PLRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
This is a Bullish indicator signaling PLRX's price could rise from here. Traders may explore going long the stock or buying call options...
For the last three days, A.I.dvisor has detected that PLRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq...
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast's time to Phase 3 data Upsized Oxford Finance debt...